Yes, provided there is no increased risk for toxicity.
American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain:

patient-centered education and surveillance related to NSAID
toxicity, especially in patients with end-organ comorbidities, because
long-term safety data for SCD are lacking, but vascular, bleeding,
and renal risks may be elevated.